Abstract
Mdm2 is a well studied oncogene and has been reported to be closely related to chemoresistance in different manners. In this article, we discuss the current knowledge of mdm2’s function in drug resistance, the novel relationship between MDM2 and Akt phosphorylation, the role of Akt signaling pathway in epithelial-mesenchymal transition, and the positive correlation among MDM2, epithelial-mesenchymal transition and drug resistance. We propose a possible pathway by which MDM2 increases drug resistance through inducing epithelial-mesenchymal transition independent of p53. This pathway may play a significant role in the tumorigenesis and chemoresistance. By targeting MDM2, we can re-activate the function of p53, inhibit the epithelial-mesenchymal transition process and thus increase cancer cells sensitivity to chemotherapy. Thus, from p53-dependent and p53-independent aspects, it may present a better strategy for cancer treatment than targeting other genes.
Keywords: Mdm2, Akt phosphorylation, p53, drug resistance, epithelial-mesenchymal transition.
Current Medicinal Chemistry
Title:MDM2 Increases Drug Resistance in Cancer Cells by Inducing EMT Independent of p53
Volume: 23 Issue: 40
Author(s): Weichao Sun and Liling Tang
Affiliation:
Keywords: Mdm2, Akt phosphorylation, p53, drug resistance, epithelial-mesenchymal transition.
Abstract: Mdm2 is a well studied oncogene and has been reported to be closely related to chemoresistance in different manners. In this article, we discuss the current knowledge of mdm2’s function in drug resistance, the novel relationship between MDM2 and Akt phosphorylation, the role of Akt signaling pathway in epithelial-mesenchymal transition, and the positive correlation among MDM2, epithelial-mesenchymal transition and drug resistance. We propose a possible pathway by which MDM2 increases drug resistance through inducing epithelial-mesenchymal transition independent of p53. This pathway may play a significant role in the tumorigenesis and chemoresistance. By targeting MDM2, we can re-activate the function of p53, inhibit the epithelial-mesenchymal transition process and thus increase cancer cells sensitivity to chemotherapy. Thus, from p53-dependent and p53-independent aspects, it may present a better strategy for cancer treatment than targeting other genes.
Export Options
About this article
Cite this article as:
Sun Weichao and Tang Liling, MDM2 Increases Drug Resistance in Cancer Cells by Inducing EMT Independent of p53, Current Medicinal Chemistry 2016; 23 (40) . https://dx.doi.org/10.2174/0929867323666160926150820
DOI https://dx.doi.org/10.2174/0929867323666160926150820 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Strategies for In Vivo siRNA Delivery in Cancer
Mini-Reviews in Medicinal Chemistry Asialoglycoprotein Receptor-Targeted Radiopharmaceuticals for Measurement of Liver Function
Current Medicinal Chemistry Cancer Estimates in Brazil Reveal Progress for the Most Lethal Malignancies
Current Topics in Medicinal Chemistry Generation of Human Single-chain Antibody to the CD99 Cell Surface Determinant Specifically Recognizing Ewing’s Sarcoma Tumor Cells
Current Pharmaceutical Biotechnology Bioactivities of Iridoids
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Alleviating Effect of Herniarin Against Ionizing Radiation-Induced Genotoxicity and Cytotoxicity in Human Peripheral Blood Lymphocytes
Current Radiopharmaceuticals Unified Multi-target Approach for the Rational in silico Design of Anti-bladder Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry DNA Methyltransferase-1 Inhibitors as Epigenetic Therapy for Cancer
Current Cancer Drug Targets Review: Alternative Splicing (AS) of Genes As An Approach for Generating Protein Complexity
Current Genomics Prostaglandin E<sub>2</sub> Receptor 4 (EP4): A Promising Therapeutic Target for the Treatment of Cancer and Inflammatory Diseases
Current Chemical Biology Current and Future Clinical Strategies in Colon Cancer Prevention and the Emerging Role of Chemoprevention
Current Pharmaceutical Design Nutritional Targeting of Cyclooxygenase-2 for Colon Cancer Prevention
Inflammation & Allergy - Drug Targets (Discontinued) Identification of a RhoA- and SRF-Dependent Mechanism of Androgen Action that is Associated with Prostate Cancer Progression
Current Drug Targets Purification and Characterization of a Novel Peroxidase from Bitter Gourd (Momordica charantia)
Protein & Peptide Letters Long-Term Survival and Cost of Treatment in Patients with Stage IIIC Epithelial Ovarian Cancer
Current Women`s Health Reviews Targeting the Nucleus: An Overview of Auger-Electron Radionuclide Therapy
Current Drug Discovery Technologies Meet Our Editorial Board Member
Current Genomics Morphologic and Molecular Backgrounds for Personalized Management of Genito-Urinary Cancers: An Overview
Current Drug Targets New and Under Explored Epigenetic Modulators in Search of New Paradigms
Medicinal Chemistry Imaging of Spinal Bone Tumors: Principles and Practice
Current Medical Imaging